Leadership Overview
Promega has 5 executives leading key functions including strategy, financial operations, information technology, global revenue, and general management.
Committed to advancing life science research, Promega delivers innovative solutions for genomics, protein analysis, and drug discovery to empower scientists worldwide.
Committed to advancing life science research, Promega delivers innovative solutions for genomics, protein analysis, and drug discovery to empower scientists worldwide.
Leadership Roles at Promega
William Linton - Chairman, Chief Executive Officer & President
William Linton, the Chairman, Chief Executive Officer & President at Promega, directs the overarching corporate strategy and long-term vision for the biotechnology manufacturer. Overseeing the development of enzymes and molecular biology tools, the Chairman, Chief Executive Officer & President ensures alignment between research initiatives and global market demands. This leadership role involves guiding the executive team through complex drug discovery landscapes while maintaining the company's commitment to scientific excellence. By fostering a culture of innovation, William Linton drives the expansion of genomics and cellular analysis portfolios across international markets. The Chairman, Chief Executive Officer & President maintains rigorous standards for product quality and operational integrity, ensuring that the organization remains a leader in the life sciences sector. Through consistent focus on sustainable growth, Linton secures the company's position as a vital partner for researchers and clinical laboratories worldwide.
Chris Yarbro - Chief Financial Officer
Chris Yarbro, the Chief Financial Officer at Promega, manages the fiscal health and capital allocation strategies for the biotechnology firm. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the company maintains the resources necessary to support extensive research and development in molecular biology. This leadership role involves collaborating with the executive board to optimize investment in genomics and protein analysis technologies. By monitoring global economic trends, Chris Yarbro directs financial operations to support expansion across diverse international markets. The Chief Financial Officer implements robust fiscal controls that facilitate efficient manufacturing processes and supply chain stability. Through strategic oversight of capital expenditures, Yarbro enables the organization to pursue long-term growth objectives while maintaining profitability. This financial stewardship supports the company's mission to provide high-quality tools for drug discovery and genetic identity applications.
Kristen Yetter - General Manager and President
Kristen Yetter, the General Manager and President at Promega, oversees the daily operational execution and organizational performance of the biotechnology manufacturer. Managing the integration of manufacturing processes with research and development goals, the General Manager and President ensures that the production of enzymes and molecular biology products meets stringent quality standards. This leadership role involves streamlining internal workflows to enhance productivity across the company's diverse product lines. By coordinating cross-functional teams, Kristen Yetter drives operational excellence in support of genomics and protein analysis initiatives. The General Manager and President maintains a focus on scaling production capabilities to meet global demand for drug discovery tools. Through effective management of resources and personnel, Yetter ensures the company remains agile in a competitive market. This operational leadership supports the organization's commitment to delivering reliable solutions for the global scientific community.
Brian Schiro - Chief Information Officer
Brian Schiro, the Chief Information Officer at Promega, architects the digital infrastructure and data management systems essential for biotechnology operations. Overseeing the integration of advanced computing platforms, the Chief Information Officer ensures that research teams possess the tools required for complex genomic data analysis and protein expression modeling. This leadership role involves securing the company's intellectual property through robust cybersecurity frameworks while facilitating seamless collaboration across global research facilities. By modernizing information systems, Brian Schiro drives operational efficiency in manufacturing and supply chain logistics. The Chief Information Officer aligns technological investments with the company's broader goals in drug discovery and cellular analysis. Through the implementation of scalable cloud solutions, Schiro supports the rapid processing of molecular biology data. This digital transformation enables the organization to maintain a competitive edge in the fast-paced life sciences industry.
Kara Machleidt - Global Chief Revenue Officer, Strategic Business Lead
Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, directs commercial growth and market penetration strategies for the biotechnology portfolio. Overseeing sales operations and customer engagement, the Global Chief Revenue Officer, Strategic Business Lead ensures that genomics and cellular analysis products reach key research institutions and clinical markets. This leadership role involves identifying emerging opportunities in drug discovery and genetic identity to expand the company's footprint. By coordinating with regional teams, Kara Machleidt drives revenue performance across North American and international territories. The Global Chief Revenue Officer, Strategic Business Lead optimizes the sales funnel to align with the company's mission of providing high-impact molecular biology tools. Through strategic partnerships and market analysis, Machleidt secures long-term commercial success. This focus on revenue growth supports the organization's ability to invest in future scientific breakthroughs and product development.
Explore Leadership Teams in Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership CD
NB
ES
SS
Hetero is a global pharmaceutical company founded in 1993 and headquartered in India with operations across Asia, Europe, North America, South America, Africa, and the Middle East. The company specializes in manufacturing generic pharmaceuticals and is recognized as a major producer of anti-retroviral medications for HIV/AIDS treatment. Hetero develops and manufactures a wide range of pharmaceutical products while maintaining research facilities and production centers worldwide.
Company Leadership RS
KS
VS
Tilray was established in 2018 in British Columbia, Canada. They specialize in the research, cultivation, production and distribution of medical cannabis and cannabinoids.
Company Leadership
BM
LB
Gufic Group is a respected player in the pharmaceutical industry, established in 1970, known for its innovative and high-quality pharmaceutical and herbal products, along with a diverse range of APIs. They are recognized as one of India's largest manufacturers of lyophilized injections, offering a variety of products including antibiotics, antifungals, and antiviral treatments. Their extensive network facilitates the supply of these products to major hospital chains and leading medical facilities across India. Gufic is committed to research and development, continuously launching advanced new products while expanding their international footprint.
Company Leadership NY
DR
SD
Frequently Asked Questions Regarding Promega Top Executives and Leadership Team
Unlock more people and company data
